The funding will support the Danfoss spin-out in the run up to the commercial launch of its insulin delivery device in 2016.
CeQur, a Switzerland-based spin-out from industrial products group Danfoss that is working on diabetes treatment technology, secured $100m in series C financing yesterday.
The round was co-led by asset management firm Woodford Investment Management and fund manager Arthurian Life Sciences, and also included investment firm Endeavor Vision, asset manager Schroders and venture capital firm VI Partners.
Spun out of Denmark-based Danfoss in 2008, CeQur’s lead product, PaQ, is a wearable insulin delivery device that supplies users with insulin for…
